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Abstract Dysregulation of splicing factor expres-
sion is emerging as a driver of human ageing; levels of
transcripts encoding splicing regulators have previ-
ously been implicated in ageing and cellular senes-
cence both in vitro and in vivo. We measured the
expression levels of an a priori panel of 20 age- or
senescence-associated splicing factors by qRT-PCR in
peripheral blood samples from the InCHIANTI Study
of Aging, and assessed longitudinal relationships with
human ageing phenotypes (cognitive decline and
physical ability) using multivariate linear regression.
AKAP17A, HNRNPA0 and HNRNPM transcript levels
were all predictively associated with severe decline in
MMSE score (p = 0.007, 0.001 and 0.008 respec-
tively). Further analyses also found expression of
these genes was associated with a performance decline
in two other cognitive measures; the Trail Making Test
and the Purdue Pegboard Test. AKAP17A was nom-
inally associated with a decline in mean hand-grip
strength (p = 0.023), and further analyses found
nominal associations with two other physical ability
measures; the Epidemiologic Studies of the Elderly-
Short Physical Performance Battery and calculated
speed (m/s) during a timed 400 m fast walking test.
These data add weight to the hypothesis that splicing
dyregulation may contribute to the development of
some ageing phenotypes in the human population.
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Introduction
There is an intimate relationship between stress
responses and successful ageing (Kourtis and Tav-
ernarakis 2011) yet the ability to respond appropri-
ately to stressful environments and to maintain
systemic homeostasis declines with age in multiple
species (Kirkland et al. 2016; Schorr et al. 2018;
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Varadhan et al. 2008). Cellular responses to external
and internal stressors are mediated at the level of
genomic plasticity, in particular at the level of the
transcriptome. Several mechanisms are known to play
a part in the diversity of response, including tran-
scriptional regulation at the level of polymerase
activity (Chen et al. 2018), post-transcriptional regu-
lation (Harvey et al. 2017), epigenetics (Guillaumet-
Adkins et al. 2017) and genomic landscape (Winick-
Ng and Rylett 2018). Alternative splicing comprises a
key part of the homeostatic response to stress (Disher
and Skandalis 2007; Martinez and Lynch 2013;
Mastrangelo et al. 2012), and dysregulation of this
process is now emerging as a new and important driver
of cellular ageing (Harries et al. 2011; Holly et al.
2013; Latorre and Harries 2017). Over 95% of genes
are capable of producing more than one mRNA
product under different conditions and alternatively-
expressed mRNAs can have profoundly different
temporal or spatial expression patterns, or demonstrate
major differences in functionality (Celotto and Grav-
eley 2001; Grumont and Gerondakis 1994; Pan et al.
2008).
Alternative splicing decisions are made by a series
of trans-acting splicing regulatory proteins termed
splicing factors. These are the Serine Arginine-rich
(SR) family of splicing factors which usually, but not
exclusively, promote splice site usage, and the
heterogeneous nuclear ribonucleoprotein (HNRNP)
family of splicing factors which are usually, but not
exclusively, associated with inhibition of splice site
usage (Cartegni et al. 2002). SR proteins and HNRNPs
bind to exon/intron splicing enhancer (ESE/ISE) or
silencer (ESS/ISS) elements in the vicinity of the
splice sites and the balance of activators and inhibitors
at any given splice site regulates splice site usage
(Smith and Valcarcel 2000). The expression levels of
splicing regulators is known to be associated with
ageing; of seven gene ontology pathways robustly
associated with age in a large cross-sectional popula-
tion study of human ageing, six were directly involved
in mRNA splicing processes (Harries et al. 2011).
Splicing factor expression is also associated with
lifespan in mice and humans (Lee et al. 2016).
We have previously observed disruption of splicing
factor expression in human senescent cells (Holly
et al. 2013; Latorre et al. 2018b), and demonstrated
that experimental manipulation of splicing factor
expression is capable of inducing rescue from the
senescent cell phenotype (Latorre et al.
2017, 2018a, c). Although we have demonstrated
epidemiological links with ageing itself, and reversal
of cellular senescence in vitro, evidence that the
phenomena we observe in vitro is linked with down-
stream ageing phenotypes is lacking. In this study, we
addressed this question by measurement of the
expression of an a priori panel of age- and senes-
cence-related splicing factor genes in human periph-
eral blood mRNA from the InCHIANTI study of
Aging. We used samples from two follow-up visits
(FU3; 2007–2010 and FU4; 2012–2014) of the
InCHIANTI study of Aging, and related their expres-
sion to changes in recorded measures of two important
human ageing phenotypes; cognitive and physical
function. We initially used the Mini Mental State
Exam (MMSE) score and mean hand-grip strength to
identify putative associations between splicing factor
expression and changes in cognitive or physical ability
respectively. We then assessed expression of these
transcripts against other cognitive and physical mea-
sures available in the dataset. In each case, a set of sub-
analyses were also performed to test the robustness of
the findings.
We found that the expression of three splicing
factor genes, HNRNPM, HNRNPA0 and AKAP17A
may be predictive for change in in this population; all
three genes were associated with cognitive decline as
measured by the Mini-Mental State Examination
(MMSE), Trail-Making Tests part A and B (TMT
A/B), and the Purdue Pegboard Test (PPT). AKAP17A
was also associated with a decline in physical ability as
measured by hand-grip strength, the Epidemiologic
Studies of the Elderly-Short Physical Performance
Battery (EPESE-SPPB) and calculated speed during a
timed 400 m fast walking test. Our data suggest that
age-associated dysregulation of splicing factor expres-
sion in ageing humans may contribute to the devel-
opment of downstream ageing outcomes.
Methods
InCHIANTI cohort and selection of participants
The InCHIANTI study of Aging is a population study
of ageing (Ferrucci et al. 2000). Participants undertook
detailed assessment of health and lifestyle parameters
at baseline, and again at three subsequent follow-ups
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(FU2; 2004–2006, FU3; 2007–2010 and FU4;
2012–2014). The present study used participants from
the third and fourth follow-up visits (FU3 and FU4).
RNA samples and clinical/phenotypic data were
already available for 698 participants at FU3. The
collection of the FU4 samples and data comprise part
of this study. During the FU4 interviews in 2012/13,
blood and clinical/phenotypic data were collected
from 455 study participants. These data were cross-
checked against RNA samples and clinical/phenotypic
data already held from FU3, to ensure that sample and
phenotypic data was available from both collections.
393 individuals fitted these criteria, of which nine died
shortly after the FU4 visit and so were excluded from
the analysis. From the remaining 384 eligible samples,
300 were randomly selected from the cohort to be
analysed for expression of splicing factor genes.
Anthropometric parameters and blood cell subtypes
in FU4 were measured as previously (Ferrucci et al.
2000).
Splicing factor candidate genes for analysis
An a priori list of splicing factor candidate genes were
chosen based on associations we had documented with
human ageing in multiple populations and in senescent
primary human cell lines in our previous work
(Harries et al. 2011; Holly et al. 2013; Latorre et al.
2017). We have also found associations of compo-
nents of this gene set with lifespan in both mice and
humans (Lee et al. 2016). The list of genes included
the positive regulatory splicing factors AKAP17A,
SRSF1, SRSF2, SRSF3, SRSF6, SRSF7, PNISR and
TRA2B, the negative regulatory splicing inhibitors
HNRNPA0, HNRNPA1, HNRNPA2B1, HNRNPD,
HNRNPH3, HNRNPK, HNRNPM, HNRNPUL2 and
the IMP3, LSM14A, LSM2 and SF3B1 core compo-
nents of the spliceosome. Expression assays were
obtained in custom TaqMan low-density array
(TLDA) format (ThermoFisher, Waltham, MA,
USA). Assay Identifiers are given in Supplementary
Table S1.
RNA collection and extraction
2.5 ml of peripheral blood was collected from each
participant into PAXgene Blood RNA Tubes (IVD)
(PreAnalytiX GmbH, Hombrechtikon, Switzerland).
Blood tubes were then treated according to the
manufacturer’s instructions and subsequently cold-
chain shipped to the UK. RNA extractions were then
carried out using the PAXgene Blood mRNA Kit
(Qiagen, Hilden, Germany), according to manufac-
turer’s instructions. Samples were assessed for RNA
quality and quantity by Nanodrop spectrophotometry
(NanoDrop, Wilmington, DE, USA).
Reverse transcription and quantitative RT-PCR
100 ng of total RNA was reverse transcribed using
SuperScript VILOTM cDNA Synthesis Kit (Ther-
moFisher, Waltham, MA, USA) in 20 ll reactions,
according to the manufacturer’s instructions. 20 ll
cDNA (reverse transcribed as indicated above) was
added to 50 ll TaqMan Universal Master Mix II, no
UNG (ThermoFisher, Waltham, MA, USA) and 30 ll
RNase-free dH2O, then loaded onto TaqMan
 Low-
Density Array 384-Well Microfluidic cards. 100lL
reaction solution was dispensed into each TLDA card
chamber and the card centrifuged twice for 1 min at
2169g to ensure distribution of solution to each well.
The expression of transcripts in each sample was
measured in duplicate replicates. Cards were run on
the 7900HT Fast Real-Time PCR System (Ther-
moFisher, Waltham, MA, USA). Amplification con-
ditions were as follows: a single cycle of 50 C for
2 min, a single cycle of 94.5 C for 10 min followed
by 40 cycles of 97 C for 30 s and 59.7 C for 1 min.
Data preparation
SDS files were uploaded to the ThermoFisher Cloud
(ThermoFisher, Waltham, MA, USA) and analysed
using the Relative Quantification qPCR App encom-
passed within the software (https://www.thermofisher.
com/uk/en/home/cloud.html). This platform was used
to manually set Baseline and Threshold for each assay
(see Supplementary Table S1 for values) and to ensure
there were no apparent outliers before further analysis.
One sample was excluded at this stage as expression
data was missing for all genes measured. Output was
imported into Excel (Microsoft, Redmond, WA, USA)
and the CT values used for analysis using the com-
parative CT method. The most stable genes for use as
endogenous controls were determined from the raw
data using the RefFinder webtool (Xie et al. 2012),
which returned the geometric mean value across all
genes measured as the most stable control, and thus the
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most appropriate for the DCT normalisation step.
Expression was then calculated relative to the median
expression for each individual transcript. Data were
log transformed to ensure normal distribution. Outlier
detection was performed in SPSS (IBM, Armonk, NY,
USA). Univariate outliers were identified using stan-
dardised z-scores, with any individual measures for
each gene falling outside the cut-off (set at three
standard deviations from the mean) being discarded.
Multivariate outliers were identified using a regression
model with Mahalanobis distance as an output, fol-
lowed by comparison of the calculated Mahalanobis
distances with the critical v2 value for the dataset
(Rasmussen 1988). One sample for which the Maha-
lanobis distance exceeded the critical v2 was dis-
carded, leaving a total of n = 298 samples to take
forward for statistical testing. The characteristics of
this final subset of participants are summarised in
Table 1.
Phenotypic outcomes for analysis
The current study analysed the associations of splicing
factor gene expression at FU3 with the following
cognitive phenotypic outcomes; MMSE score, Trail-
Making-Test (TMT A&B) and Purdue Pegboard Test
(as measures of cognitive function), along with hand-
grip strength, EPESE-SPPB composite score and
calculated speed during a 400 m fast walk (as
measures of physical ability).
MMSE score was measured at both FU3 and FU4
using the standard test, after which the data was
corrected to adjust for incomplete tests. This was
calculated using the score attained as a proportion of
the maximum possible points for the parts of the test
that were completed. Decline in MMSE score was
calculated by subtracting the score at FU4 from the
score at FU3. Time taken to complete the Trail-
Making-Tests part A and B were measured in seconds
at both FU3 and FU4 using the standard tests. Decline
in performance on the tests was calculated by
subtracting the score at FU4 from the score at FU3.
Decline in seconds was then converted to a decline in
fractions of a minute prior to analysis. The Purdue
Pegboard Test was administered as standard (although
data for the assembly portion of the test was not
available), and scores for number of pegs placed in the
board for right-hand, left-hand and both-hands were
summed to give a total number of pegs placed during
the test. Decline in performance on the test was
calculated by subtracting the total number of pegs
placed at FU4 from the total number of pegs placed at
FU3.
Hand-grip strength was measured in kilograms at
both FU3 and FU4 using a dynamometer, with two
separate measurements taken for each hand. Mean
hand-grip strength was used for the analyses in this
study, and was calculated as the mean of all 4 hand-
grip strength measurements across both hands.
Decline in mean hand-grip strength was calculated
by subtracting the measurement at FU4 from the
measurement at FU3. The EPESE-SPPB was admin-
istered and scored as described elsewhere (Guralnik
et al. 1994), and a composite score generated from the
sub-scores of the three activities performed: repeated
chair-stand, standing balance and 4 m normal pace
walk. Decline in performance was calculated by
subtracting the composite score at FU4 from the
composite score at FU3. The 400 m fast walk was
performed by completing 20 laps of a 20 m circuit
with a maximum of two stops if the subject required.
Speed in m/s was calculated over the entire distance
(any individuals who did not complete the test were
excluded from further analysis), and decline in
performance was calculated by subtracting the speed
at FU4 from the speed at FU3.
Sub-analyses for robustness testing
For all phenotypes, any associations found in the full
cohort were then tested for robustness through four
sub-analyses on different subsets of the data.
First, individuals with the lowest initial scores (at
FU3) were excluded from the analysis, to avoid
confounding due to the inclusion of participants
already on a trajectory to decline. For MMSE score,
the cut-off was set at C28, as a score above 28 is
clearly indicative of a lack of cognitive impairment. In
the case of mean hand-grip strength, the cut-offs used
were those previously reported as a consensus defini-
tion of sarcopenia by The European Working Group
on Sarcopenia in Older People (EWGSOP) (Cruz-
Jentoft et al. 2010), i.e.\ 20 kg for females and\
30 kg for males. For all the other phenotypes
analysed, the dataset at FU3 was divided into quintiles,
with the lowest scoring quintile being excluded from
this sub-analysis.
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Table 1 Participant details
(A)
Follow-up 3 Follow-up 4
n % n %
Participants 298 100 298 100
Age (years)
30–39 21 7.05 11 3.69
40–49 31 10.40 28 9.40
50–59 31 10.40 28 9.40
60–69 35 11.74 34 11.41
70–79 111 37.25 38 12.75
80–89 67 22.48 142 47.65
90–100 2 0.67 17 5.70
Gender
Male 136 45.64 136 45.64
Female 162 54.36 162 54.36
Pack years smoked (lifetime)
None 159 53.36 No Data
\ 20 79 26.51 No Data
20–39 44 14.76 No Data
40 ? 16 5.37 No Data
Site
Greve 140 46.98 140 46.98
Bagno a Ripoli 158 53.02 158 53.02
Education level attained
Nothing 28 9.4 24 8.05
Elementary 121 40.6 125 41.95
Secondary 51 17.11 59 19.80
High school 46 15.44 58 19.46
Professional school 33 11.07 11 3.69
University or equivalent 19 6.38 21 7.05
(B)
Follow-up 3 Follow-up 4
Mean Std. dev. Min Max Mean Std. dev. Min Max
Age (years) 67.69 15.68 30.00 94.00 72.92 15.68 35.00 100.00
BMI 26.97 4.27 15.01 42.99 26.86 4.42 13.39 41.19
White blood cell count (n, K/ll) 6.39 1.60 2.10 13.00 6.16 1.72 2.30 16.59
Neutrophils (%) 56.61 8.61 26.20 81.20 56.50 9.23 22.20 88.40
Lymphocytes (%) 31.56 8.04 9.80 59.90 32.47 8.70 8.30 63.30
Monocytes (%) 8.08 2.22 3.70 21.30 7.36 2.28 1.60 24.40
Eosinophils (%) 3.19 2.20 0.00 21.50 3.21 2.02 0.00 13.00
Basophils (%) 0.55 0.20 0.10 1.30 0.47 0.29 0.00 2.10
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Second, an analysis was carried out using only the
eldest participants aged C 70 years at FU3 to exclude
any potential confounding effects from younger
participants. Declining cognitive and physical ability
are predominantly features of ageing, and measures
such as mean hand-grip strength and MMSE are likely
to perform poorly in measuring change of function in
young, non-compromised individuals.
Third, some individuals measured showed an
apparent improvement in performance over time
between FU3 and FU4, which may reflect a degree
of measurement error. To test this, we first calculated
an allowed error of 5% (as a fraction of the total range
of change measured), then removed any individuals
with scores showing an increase greater than the
allowed error between the follow-ups, for each
phenotype.
Finally, participants were categorised into mild or
severe decline classes, to assess whether the associ-
ations seen were specific to either group of individuals.
Decline in MMSE score was categorised for sub-
analysis as follows; ‘No decline’ (score change of - 1
to ? 7, based on a 5% allowable error calculated as
described above), ‘Mild decline’ (- 2 to - 8), and
‘Severe decline’ (- 9 to - 22). While opinion differs
as to what amounts to a significant rate of change in
MMSE during cognitive decline, we chose to classify
a severe decline as a drop in MMSE score of[ 3 per
annum on average, based on information from several
previous studies (Clark et al. 1999; Hensel et al. 2007;
McCarten et al. 2004). Analysis of categorised MMSE
decline was carried out using the ‘No decline’ class as
the comparator.
Decline in mean hand-grip strength was categorised
as follows; quintiles of change in mean hand-grip were
calculated separately for males and females, after
which the respective 20% of males and females
displaying the largest decline in mean hand-grip
strength were together designated as the ‘Severe
decline’ class (mean hand-grip change of - 3.75 kg
to - 22 kg). The remainder of the cohort was divided
into ‘No decline’ (- 1 kg to ?15.5 kg, based on a 5%
allowable error calculated as described above) and
‘Mild decline’ (- 1.25 kg to - 6 kg) categories.
Analysis of categorised mean hand-grip strength
decline was carried out using the ‘No decline’ class
as the comparator.
For all other measures used for analysis, categori-
sation was carried out by dividing using the cohort into
quintiles based on the change in score, and the quintile
with the greatest decline in performance designated as
the ‘Severe decline’ class. The remainder of the cohort
was divided into ‘No decline’ and ‘Mild decline’
classes using the same method as described above for
MMSE and mean hand-grip strength. Analysis of
categorised variables was carried out using the ‘No
decline’ class as the comparator in all cases.
Statistical analysis
Associations of gene expression with cognitive and
physical phenotype measures were assessed using
Table 1 continued
(C)
n Follow-up 3 Follow-up 4
Mean Std. dev. Min Max Mean Std. dev. Min Max
Corrected MMSE score 296 27.22 3.18 14.00 30.00 25.71 5.11 0.00 30.00
TMT-A (mins) 268 0.91 0.62 0.23 5.00 1.13 0.83 0.25 5.00
TMT-B (mins) 179 1.56 1.02 0.47 5.00 1.91 1.19 0.52 5.00
PPT (total pegs placed) 257 64.77 13.38 26 98 61.60 16.45 17 103
Mean hand-grip strength (Kg) 285 29.67 12.28 10.00 70.75 28.11 12.14 5.00 65.50
EPESE-SPPB (composite score) 276 11.10 1.59 0 12 10.09 2.95 0 12
400 m fast walk speed (m/s) 206 1.41 0.25 0.73 2.18 1.26 0.29 0.47 2.03
Characteristics of the InCHIANTI participants used in the present study. Panel A shows summary of non-clinical details, panel B
shows summary results of clinical/laboratory tests and panel C shows summary results of phenotypic measures used for analysis
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multivariate linear regression models. All models
were adjusted for age, sex, BMI, smoking (lifetime
pack-years), highest education level attained, study
site, TLDA batch and cell counts (neutrophils, lym-
phocytes, monocytes, eosinophils and overall white
blood cell count). Regressions were carried out in
STATA SE v15.1 (StataCorp, College Station, TX,
USA). Pearson correlation tests were carried out in
SPSS (IBM, Armonk, NY, USA) to assess relation-
ships between splicing factor expression levels, phe-
notypic measures and established biomarkers of
ageing.
Results
AKAP17A, HNRNPA0 and HNRNPM transcript
levels are associated with change in MMSE score
MMSE is a commonly used measure of cognitive
decline (Clark et al. 1999; Hensel et al. 2007;
McCarten et al. 2004). HNRNPM expression showed
a significant association with decline in MMSE score
in the entire cohort (b-coefficient- 0.005, p = 0.006),
with HNRNPA0 also showing a nominal association
(b-coefficient - 0.003, p = 0.019). In both cases
individuals with lower expression levels at the early
time-point (FU3) had subsequently experienced a
greater drop in MMSE score (Fig. 1a, Supplementary
Table S2). The remaining splicing factor genes did not
demonstrate associations between MMSE and
expression.
To test the robustness of our findings we carried out
four sub-analyses. Similar sub-analyses were also used
on all other associations found in the present study and
full details can be found in the Methods. In brief,
regression models were repeated on the following
subsets of data: firstly we removed individuals with
low starting scores, secondly only individuals over
70 years of age were included, thirdly any individuals
showing an increase in performance over time were
Fig. 1 Associations of splicing factor expression with MMSE
score. Forest plots showing splicing factor expression in relation
to a decline in corrected MMSE scores and b mean hand-grip
strength in the InCHIANTI human ageing cohort. Individual
splicing factors are indicated on the y-axis while b-coefficients
of change in log expression per unit change in measurements are
given on the x-axis. Positive values denote an increase in
expression with larger decline in score while negative values
denote a decrease in expression with larger decline in score.
Error bars denote 95% confidence intervals, significance is
shown using stars as follows: *p\ 0.05, **p\ 0.01. Stars
indicated in black denote associations which meet multiple
testing thresholds, while those in grey represent nominal
associations
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excluded, and finally participants were categorised
into ‘mild’ or ‘severe’ decline classes.
Although AKAP17A showed only a trend with
MMSE decline in the initial analysis, the observation
that it had the largest b-coefficient, coupled with a
suggestive p value of 0.077 merited its inclusion in
these further analyses. As can be seen in Figs. 2a, 3a
and 4a (Supplementary Table S3), both HNRNPA0
and HNRNPM remained at least nominally associated
with decline in MMSE score across all sub-analyses,
and significantly associated with severe decline in the
categorised analysis. AKAP17A on the other hand was
only nominally associated with decline in MMSE in
the sub-analysis excluding the individuals displaying
an apparent improvement over time, but in the
categorised analysis a significant association was also
seen between AKAP17A expression and severe
decline.
To assess whether these findings represent inde-
pendent effects or could be driven by co-ordinate
expression of the three genes, we carried out correla-
tion analysis. Correlations between the three genes in
question were only moderate (R values: HNRNPA0 &
HNRNPM: 0.282, HNRNPA0 & AKAP17A: 0.239,
HNRNPM & AKAP17A: 0.440 (Supplementary
Table S4).
Expression of HNRNPA0, HNRNPM
and AKAP17A transcripts are also associated
with two other measures of cognitive ability
The Trail Making Test (TMT) is another widely used
test for cognitive assessment which addresses visual
scanning, graphomotor speed and executive function
(Llinas-Regla et al. 2017). Figures 2b, c, 3b, c and 4b,
c (Supplementary table S5) show AKAP17A and
bFig. 2 Sub-analyses of AKAP17A associations with measures
of cognitive function. Bar charts showing the associations
between expression of AKAP17A and change in performance in
tests of cognitive function. a shows associations with MMSE
score, b shows associations with TMT-A, c shows associations
with TMT-B and d shows associations with PPT. Different sub-
analyses are plotted separately as indicated in the figure legend.
Error bars denote 95% confidence intervals, significance is
shown using stars as follows: *p\ 0.05, **p\ 0.01. Stars
indicated in black denote associations which meet multiple
testing thresholds, while those in grey represent nominal
associations
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HNRNPA0 transcript levels were at least nominally
associated with increased time to complete TMT-A,
both in the full cohort (b-coefficients 0.057 and 0.028,
p = 0.009 and 0.004 for AKAP17A and HNRNPA0
respectively) and in all sub-analyses with the excep-
tion of the categorised analysis for AKAP17A.
HNRNPM expression was nominally associated with
increased time to complete TMT-B, but only in the full
cohort (b-coefficient 0.026, p = 0.036) and cate-
gorised analyses. In all cases, lower expression levels
were associated with an increase in the time taken to
complete the test (i.e. a decline in performance).
The Purdue Pegboard Test (PPT) was originally
developed as a tool to evaluate fine manual dexterity
but has since been used for assessments of cognitive
function (Brown et al. 1993; Zakzanis et al. 1998). As
shown in Figs. 2d, 3d and 4d (Supplementary
table S5), all three transcripts were nominally associ-
ated with a performance decline in the full cohort (b-
coefficients - 0.005, - 0.002 and - 0.002,
p = 0.012, 0.047 and 0.044 for AKAP17A, HNRNPA0
and HNRNPM respectively). While AKAP17A and
HNRNPA0 transcript levels were found to be signif-
icantly associated with performance decline in some
of the sub-analyses, HNRNPM showed no such further
associations.
Pearson correlations were also carried out to assess
relationships between the aspects of cognition being
measured by MMSE, TMT and PPT. Correlations
between the measures were relatively weak (R values
range from - 0.381 to 0.322, see Supplementary
Table S6a).
bFig. 3 Sub-analyses of HNRNPA0 associations with measures
of cognitive function. Bar charts showing the associations
between expression of HNRNPA0 and change in performance in
tests of cognitive function. a shows associations with MMSE
score, b shows associations with TMT-A, c shows associations
with TMT-B and d shows associations with PPT. Different sub-
analyses are plotted separately as indicated in the figure legend.
Error bars denote 95% confidence intervals, significance is
shown using stars as follows: *p\ 0.05, **p\ 0.01. Stars
indicated in black denote associations which meet multiple
testing thresholds, while those in grey represent nominal
associations
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Expression of AKAP17A transcript is associated
with mean hand-grip strength
Hand-grip strength, a measure of muscle weakness, is
a useful indicator of physical functioning and health-
related quality of life in the elderly (Bohannon 2015).
Of the transcripts tested, only AKAP17A transcript
levels were nominally associated with decline in hand-
grip strength between FU3 and FU4 (b-coefficient
- 0.006, p = 0.023) (Fig. 1b, Supplementary
Table S7). As shown in Fig. 5a (Supplementary
Table S8), robustness testing of this finding revealed
one nominal and one significant association in the sub-
analyses, and no associations with the categorised
data.
Expression of AKAP17A transcript is
also associated with two other measures
of physical ability
The Epidemiologic Studies of the Elderly-Short
Physical Performance Battery (EPESE-SPPB) is a
validated measure of lower body function and is
predictive of several important health outcomes,
including mortality (Pavasini et al. 2016). AKAP17A
expression was found to be nominally associated with
decline in the EPESE-SPPB composite score (b-
coefficient - 0.011, p = 0.048), and as can be seen in
Fig. 5b (Supplementary Table S9), subsequent testing
showed it also to be nominally associated in two of the
sub-analyses.
Another measure of physical ability that was
available in the data set was the calculated speed (m/
s) during a timed 400 m fast walking test. Once again,
AKAP17A expression was found to be nominally
associated with decline in walking speed (b-
bFig. 4 Sub-analyses of HNRNPM associations with measures
of cognitive function. Bar charts showing the associations
between expression of HNRNPM and change in performance in
tests of cognitive function. a shows associations with MMSE
score, b shows associations with TMT-A, c shows associations
with TMT-B and d shows associations with PPT. Different sub-
analyses are plotted separately as indicated in the figure legend.
Error bars denote 95% confidence intervals, significance is
shown using stars as follows: *p\ 0.05, **p\ 0.01. Stars
indicated in black denote associations which meet multiple
testing thresholds, while those in grey represent nominal
associations
123
658 Biogerontology (2019) 20:649–663
coefficient - 0.252, p = 0.013). Figure 5c (Supple-
mentary Table S9) shows that this nominal association
only held true in one sub-analysis.
Finally, Pearson correlations were carried out to
assess relationships between the aspects of physical
ability being measured. Again, correlations between
the measures were relatively weak (R values range
from 0.217 to 0.357, see Supplementary Table S6b).
HNRNPA0, HNRNPM and AKAP17A transcripts
show correlations with known biomarkers
of ageing
To test whether these transcripts might share expres-
sion patterns with levels of recognised biomarkers of
ageing (Xia et al. 2017), where such measures were
available in our dataset, we carried out Pearson
correlations between transcript expression levels and
measurements of interleukin-6 (IL-6), albumin and
total erythrocyte numbers. Significant correlations
were found between: AKAP17A expression and IL-6
levels (R value = 0.144, p = 0.013); HNRNPA0
expression and both IL-6 and erythrocyte number (R
values = - 0.200 and 0.115, p = 0.001 and 0.048
respectively); HNRNPM expression and albumin
levels (R value = - 0.137, p = 0.018).
Discussion
The human genome is equipped with mechanisms to
generate transcriptomic diversity from a relatively
small DNA complement (Nilsen and Graveley 2010).
This transcriptomic diversity underpins our ability to
respond appropriately to internal and external envi-
ronmental challenges, while the failure of such cellu-
lar stress responses contributes to ageing itself and to
age-related diseases (Kourtis and Tavernarakis 2011).
Alternative splicing is one of the major mechanisms
for generation of such diversity (Kelemen et al. 2013),
and is regulated by the combinatorial binding of a set
of trans-acting activating and inhibitory proteins
bFig. 5 Sub-analyses of AKAP17A associations with measures
of physical ability. Bar charts showing the associations between
expression of AKAP17A and change in performance in tests of
physical ability. a shows associations with mean hand-grip
strength, b shows associations with the EPESE-SPPB composite
score and c shows associations with calculated speed (m/s)
during a 400 m fast walking test. Different sub-analyses are
plotted separately as indicated in the figure legend. Error bars
denote 95% confidence intervals, significance is shown using
stars as follows: *p\ 0.05, **p\ 0.01. Stars indicated in black
denote associations which meet multiple testing thresholds,
while those in grey represent nominal associations
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termed splicing factors to cis- sequence control
elements (Smith and Valcarcel 2000). Dysregulation
of splicing factor expression occurs with human
ageing at the epidemiological and cellular levels
(Harries et al. 2011; Holly et al. 2013), and is also
associated with longevity in animal models (Lee et al.
2016). These changes are drivers of cellular ageing,
since restoration of splicing factor levels is able to
reverse multiple senescence phenotypes in aged
human cells in vitro (Latorre et al. 2017, 2018a, c).
In the work described here, we provide evidence that
changes in splicing factor expression are not only
present in in vitro data, but may also contribute to the
development of downstream ageing phenotypes in
older people. We report predictive associations
between the transcript expression levels of three
splicing factor genes, HNRNPM, HNRNPA0 and
AKAP17A with several ageing phenotypes in a human
population study, the InCHIANTI study of Aging
(Ferrucci et al. 2000).
HNRNPM, HNRNPA0 and AKAP17A transcript
levels were predictively associated with a decline in
MMSE score as well as a decline in performance on
the Trail-Making Test parts A & B and the Purdue
Pegboard Test. Associations between transcript
expression of all three genes and ageing phenotypes
were strongest in the individuals with severe cognitive
decline as measured by MMSE. It is possible that these
three splicing factors are not independently associated
with the traits in question, but correlations between
them are only moderate. HNRNPM and HNRNPA0
encode splicing inhibitor proteins that have roles in
determining the splicing patterns of several genes with
relevance to brain physiology. TDP-43 is one of the
major proteins involved with Amyotrophic lateral
sclerosis (ALS) and Frontotemporal Dementia (FTD)
in humans (Orr 2011). HNRNPM and HNRNPA0 are
both known to interact with TDP-43 (Couthouis et al.
2011), and mutations in other HNRNPs have been
described in patients with ALS (Calini et al. 2013). In
Drosophila species, depletion of the fly homologue of
HNRNPM (Rump) is associated with loss of neuronal
dendritic terminal branches; a phenotype that could be
partially restored by the addition of a Rump transgene
(Xu et al. 2013). HNRNPM has also been demon-
strated to directly regulate alternative splicing of the
dopamine receptor 2 (DRD2) gene, whereby it inhibits
the inclusion of exon 6 (Park et al. 2011). DRD2 splice
variants have previously been implicated with
schizophrenia and impaired cognitive function in
humans (Cohen et al. 2016; Kaalund et al. 2014).
Similarly, increased protein expression of HNRNPA0
in hippocampus has been shown to be associated with
memory formation and consolidation in mice (Ferreira
et al. 2016). AKAP17A, otherwise known as SFSR17A,
is an X-linked gene encoding a splicing regulatory
factor that also has roles in targeting protein kinase A
anchoring protein to splicing factor compartments
(Jarnaess et al. 2009). It is a poorly characterised gene,
but has been previously associated with the develop-
ment of Alzheimer’s disease; sequences deriving from
this gene appear twice amongst probes that best
differentiate Alzheimer’s disease brain samples from
controls (Lunnon et al. 2013).
AKAP17A was also found to be associated with
decline over time in measures of physical function,
although the sporadic nature of replication of this
association in the sub-analyses suggests that either this
finding is less robust, or the measurements themselves
are more subject to variation. No functional role for
AKAP17A has previously been reported in relation to
muscle function.
Although the changes reported here represent
changes in peripheral blood, similar changes to
splicing regulation have been reported in senescent
cell lines from other, less accessible tissues (Latorre
et al. 2017, 2018b). Splicing factor expression is
ubiquitous, although changes in the exact composition
of the splicing factor milieu will occur from tissue to
tissue. We postulate that the expression patterns of
splicing factors in peripheral blood may at least partly
reflect changes in less accessible tissues. We previ-
ously demonstrated that senescence-related changes in
splicing factor expression in endothelial cells and
cardiomyocytes are preserved in human peripheral
blood, and resultant changes in the alternative splicing
of the VEGFA gene are associated with incident and
prevalent coronary artery disease (Latorre et al.
2018b). Both cognitive decline and deterioration in
muscle strength also have a significant inflammatory
component (Harries et al. 2012; Marottoli et al. 2017).
Our study has several strengths; the use of a
longitudinal population study has allowed some
assessment of causality of effect. Placed in the context
of the known dysregulation of splicing factor expres-
sion in human and animal ageing, their associations
with longevity in both animals and humans (Heintz
et al. 2017; Lee et al. 2016) and the observation that
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correction of splicing factor levels is sufficient to
reverse senescence phenotypes in vitro (Latorre et al.
2017) suggests that these changes may be a driver of
ageing rather than an effect. The data presented here
suggest that the presence of dysregulated splicing
factor transcripts before the emergence of overt
disease in peripheral blood may contribute to the
development of age-related phenotypes such as cog-
nitive decline. Our finding that expression of these
transcripts correlate with established biomarkers of
ageing is also suggestive that they may be indicative of
future outcomes. Our study is not without limitations
however; we have only assessed splicing factor
expression at the level of the mRNA transcript for
reasons of practicality. It is possible that processes
such as post-transcriptional regulation of mRNA
transcripts or altered protein kinetics may also
contribute and would not be identified in our study.
However, the observation of phenotypic changes in
senescent cells in vitro strongly suggests that these
changes may also occur at the protein level. Our study
cohort is also relatively small in comparison to some
resources. It is however exquisitely well characterised
and features longitudinal waves of samples which
many other studies do not. These observations require
replication in an additional dataset in the future.
However, we have measures from two waves of the
study, which although they comprise the same people,
represent completely separate sample collection,
sample handling and analytical subsets.
We recognise that although an adjustment for
multiple testing has been applied at the level of
phenotype (i.e. accounting for six measurements)
throughout this study, there remains a risk of Type I
error in the results presented by using a significance
level of p = 0.0083 as the corrected threshold. How-
ever, the genes tested represented an a priori list on the
basis of known associations with age or cellular
senescence (Harries et al. 2011; Holly et al. 2013), and
we show here that although moderate, correlations do
exist between splicing factor expression levels as well
as between the measured phenotypic outcomes (Sup-
plementary Tables S4 and S6), all of which complicate
a sensible implementation of multiple testing criteria.
It is also possible that the statistical power of this study
may be limited given the number of samples and the
observed effect sizes, leading to potential inflation of
Type II error. Therefore, either Bonferroni or Ben-
jamini–Hochberg correction for both the number of
genes and phenotypes seem likely to be overly
stringent for this dataset, however the issue of multiple
testing persists, so without independent validation of
the findings presented here, we must be conservative
with any interpretation of these results.
We present here evidence to suggest that expression
levels of HNRNPM, HNRNPA0 and AKAP17A genes
may be associated with cognitive decline, whilst
AKAP17A levels may be associated with decline in
physical performance in a human population. These
findings suggest that the age-related splicing factor
changes we have previously reported in vitro and
in vivo may contribute to the development of down-
stream ageing phenotypes in older humans. Given
validation of these findings in an independent data set,
splicing factor expression could comprise a relatively
non-invasive biomarker of cognitive decline or phys-
ical ability in the future, which could be assessed from
samples collected from routine screening of the
vulnerable people in the population.
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